Brain Cancer | Specialty

The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Temferon Lands FDA Orphan Drug Status for Glioblastoma Multiforme

March 2nd 2023

The FDA has granted an orphan drug designation to Temferon for use as a potential therapeutic option in patients with glioblastoma multiforme.

FDA Grants Orphan Drug Designation to BEA-17 for Glioblastoma

February 1st 2023

The FDA has granted an orphan drug designation to BEA-17 for the treatment of patients with glioblastoma.

Dr. Ahluwalia on the Evaluation of SurVaxM With Temozolomide in Newly Diagnosed Glioblastoma

January 10th 2023

Manmeet Singh Ahluwalia, MD, discusses the evaluation of SurVaxM in combination with oral temozolomide in patients with newly diagnosed glioblastoma.

FDA Grants Orphan Drug Designation to Azeliragon for Glioblastoma

January 10th 2023

The FDA has granted an orphan drug designation to azeliragon for the treatment of patients with glioblastoma.

Tovorafenib Elicits Responses in Recurrent or Progressive Pediatric Low-Grade Glioma

January 9th 2023

Tovorafenib monotherapy generated responses in patients with recurrent or progressive pediatric low-grade glioma.

FDA Grants Breakthrough Device Designation for Blood Test for Inaccessible Brain Tumors

January 4th 2023

The FDA has granted breakthrough device designation for the TriNetra™-Glio blood test to help in the diagnosis of brain tumors.

EMA Committee Advises Against Approval of Omburtamab for Neuroblastoma

January 3rd 2023

The European Committee for Medicinal Products for Human Use has announced that it does not support the marketing authorization of omburtamab for the treatment of patients with central nervous system/leptomeningeal metastasis from neuroblastoma.

A New Take on Preclinical Drug Trials for Glioblastoma Treatment

December 14th 2022

The Ivy Brain Tumor Center at Barrow Neurological Institute in Phoenix, Arizona, is attempting to change the way preclinical studies are developed and conducted to assess the efficacy of drugs for glioblastoma multiforme.

FDA Issues Complete Response Letter for Omburtamab BLA for Pediatric Metastatic Neuroblastoma

December 2nd 2022

The FDA has issued a complete response letter to the biologics license application seeking the approval of 131I-omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma.

FDA Grants Orphan Drug Designation to AUM302 for Neuroblastoma

December 2nd 2022

The FDA has granted an orphan drug designation to AUM302 for the treatment of patients with neuroblastoma.

DCVax-L Improves Survival in Glioblastoma

November 18th 2022

Autologous tumor lysate-loaded dendritic cell vaccination used in combination with standard-of-care treatment extended overall survival for patients with newly diagnosed glioblastoma as well as those with recurrent disease.

ODAC Votes Against Omburtamab for Pediatric Metastatic Neuroblastoma

October 31st 2022

In a 16 to 0 vote, the FDA’s Oncologic Drugs Advisory Committee voted that sufficient evidence has not been provided to conclude that 131I-omburtamab improves overall survival for pediatric patients with central nervous system /leptomeningeal metastases from neuroblastoma.

FDA Raises Questions About BLA for Omburtamab in Pediatric Metastatic Neuroblastoma

October 27th 2022

The FDA has expressed concern about the efficacy of 131I-omburtamab prior to a meeting of the regulatory agency’s ODAC to examine data supporting the BLA seeking the agent’s approval for the treatment of pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma.

Bevacizumab Plus Reirradiation Improves PFS in Glioblastoma Multiforme

October 24th 2022

Bevacizumab along with reirradiation extended progression-free survival compared with bevacizumab alone for patients with recurrent glioblastoma multiforme.

177Lu-FAP-2286 Displays Preliminary Antitumor Activity in Advanced or Metastatic Solid Tumors

October 18th 2022

Lutetium-177-FAP-2286 produced preliminary evidence of antitumor activity with a manageable safety profile in patients with advanced or metastatic solid tumors, according to data from the phase 1/2 LuMIERE trial.

FDA Approves Bevacizumab-adcd Biosimilar in Six Solid Tumors

September 28th 2022

The FDA has approved bevacizumab-adcd, a bevacizumab biosimilar, for the treatment of six types of cancer.

EMA Grants Orphan Drug Designation to CAN-2409 for Glioma

September 16th 2022

The European Medicines Agency Committee for Orphan Medical Products has granted an orphan drug designation to CAN-2409 for the treatment of patients with glioma.

Higher-Dose Rhenium-186 Nanoliposome Demonstrates OS Advantage in Recurrent Glioma

September 9th 2022

Rhenium-186 nanoliposome administered at doses exceeding 100 Gy demonstrated promising safety and efficacy results in patients with recurrent glioma.

FDA Grants Orphan Drug Designation to WP1122 for Glioblastoma Multiforme

September 8th 2022

The FDA has granted an orphan drug designation to WP1122 as a potential therapeutic option for patients with glioblastoma multiforme.

ASTRO Releases Clinical Guidelines for Radiation Therapy in IDH-Mutant Glioma

September 1st 2022

For the first time, the American Society for Radiation Oncology has issued recommendations on the use of radiation therapy to treat patients with IDH-mutant grade 2 and grade 3 diffuse glioma, including oligodendroglioma and astrocytoma.